Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Recruiting · NCT06613334 · Interventional (participants receive a specific treatment) · Lead sponsor: Centre Hospitalier St Anne
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive impairment and social isolation. Treatments with antipsychotics have proven effective in improving their living conditions, but poor compliance results in relapses and rehospitalizations for the majority of patients, which often results in a worsening of residual symptoms. The prevention of these relapses is a major issue in the care of these patients and frequent monitoring is necessary. The use of a simple, rapid and inexpensive tool to monitor symptoms and treatment effect in schizophrenia could improve the effectiveness of the treatment of these patients and prevent relapses. Speech is a good candidate as a biomarker in the monitoring of patients with schizophrenia. Schizophrenia is accompanied by speech disorders including poor speech, variations in tone or intensity or even difficulties in organizing speech.
Who can take part
Inclusion criteria
- Affiliated to a social security or other social protection scheme
- Diagnosed with schizophrenia according to the DSM-5 (code F20)
- Stable state without duration criteria
- Main treatment with risperidone or paliperidone, aripiprazole, olanzapine in oral or long-acting injectable form
- Complementary treatment with an antipsychotic for anxiolytic or sedative purposes: chlorpromazine, loxapine or cyamemazine
- Able to speak and read French
- Able to perform speech evaluations
- Able to answer questionnaires on smartphone
- May be under curatorship or guardianship
- Agreeing to participate in the study and with informed consent signed by the subject, as well as by the legal representative in the case of a person under curatorship or guardianship
Exclusion criteria
- Suffering from a pathology that impairs French
- Suffering from a neurological pathology: multiple sclerosis, Parkinson's disease, Huntington's disease or neurodegenerative disease
- Treatment with lithium salts
- Anti-epileptic treatment
- Participant in another study involving medication
Where it is running
2 locations listed.
- Groupe Hospitalo-Universitaire Paris Psychiatrie & Neurosciences - Paris, France
- Groupe Hospitalo-Universitaire Paris Psychiatrie et Neurosciences, Paris - Paris, Paris, France